Results 221 to 230 of about 7,657 (243)

Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients

Journal of Cellular and Molecular Medicine, 2020
Irene Faravelli, Megi Meneri, Daniele Velardo   +2 more
exaly  

Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data

Journal of Clinical Medicine, 2023
Andrej Belančić, Tea Strbad, Dinko Vitezic   +2 more
exaly  

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Lancet, The, 2016
Richard S Finkel, Claudia A Chiriboga, John W Day   +2 more
exaly  

Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen

Journal of Pediatrics, 2020
Alice Pirola, EMILIO ALBAMONTE, Marika Pane   +2 more
exaly  

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

Neuromuscular Disorders, 2019
Darryl C De Vivo, Enrico Bertini, Kathryn J Swoboda   +2 more
exaly  

Nusinersen/onasemnogene abeparvovec

Reactions Weekly, 2022
openaire   +1 more source

Nusinersen/onasemnogene-abeparvovec

Reactions Weekly, 2020
openaire   +2 more sources

Nusinersen: A Treatment for Spinal Muscular Atrophy

Annals of Pharmacotherapy, 2019
Cheri K Walker, Debra L Stevens
exaly  

Plecanatide, Nusinersen, and Obeticholic acid

Journal of the American Pharmacists Association, 2017
Daniel A, Hussar, Deborah K, Douglas
openaire   +2 more sources

Effectiveness and Safety of Nusinersen Among Adults with 5q-Spinal Muscular Atrophy: A Multicenter Disease Registry in China

Advances in Therapy
Yi Dai, Xiaoli Yao, Wenhua Zhu, Yuying Zhao, Huifang Shang, Juanjuan Chen, Qiang Meng, Yaling Liu, Wanjin Chen, Liqiang Yu, Lu Shen, D. Hong, Ken Chen, Li Zhang, Maerhaba Mai, Liying Cui   +15 more
semanticscholar   +1 more source